DK1492789T3 - Tropanderivater som CCR5-modulatorer - Google Patents

Tropanderivater som CCR5-modulatorer

Info

Publication number
DK1492789T3
DK1492789T3 DK03710080T DK03710080T DK1492789T3 DK 1492789 T3 DK1492789 T3 DK 1492789T3 DK 03710080 T DK03710080 T DK 03710080T DK 03710080 T DK03710080 T DK 03710080T DK 1492789 T3 DK1492789 T3 DK 1492789T3
Authority
DK
Denmark
Prior art keywords
tropane derivatives
ccr5 modulators
ccr5
modulators
tropane
Prior art date
Application number
DK03710080T
Other languages
English (en)
Inventor
Patricia Ann Basford
Peter Thomas Stephenson
Stefan Colin John Taylor
Anthony Pfizer Global Rrc Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208071.1A external-priority patent/GB0208071D0/en
Priority claimed from GB0301575A external-priority patent/GB0301575D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1492789T3 publication Critical patent/DK1492789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
DK03710080T 2002-04-08 2003-03-31 Tropanderivater som CCR5-modulatorer DK1492789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208071.1A GB0208071D0 (en) 2002-04-08 2002-04-08 Tropane derivatives useful in therapy
GB0301575A GB0301575D0 (en) 2003-01-23 2003-01-23 Tropane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
DK1492789T3 true DK1492789T3 (da) 2006-09-11

Family

ID=28793308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03710080T DK1492789T3 (da) 2002-04-08 2003-03-31 Tropanderivater som CCR5-modulatorer

Country Status (41)

Country Link
EP (1) EP1492789B1 (da)
JP (2) JP3793200B2 (da)
KR (1) KR100734685B1 (da)
CN (1) CN1324025C (da)
AP (1) AP1789A (da)
AR (1) AR039383A1 (da)
AT (1) ATE328882T1 (da)
AU (1) AU2003214503B2 (da)
BR (1) BR0309118A (da)
CA (1) CA2481482C (da)
CR (1) CR7514A (da)
CU (1) CU23282A3 (da)
CY (1) CY1106114T1 (da)
DE (1) DE60305903T2 (da)
DK (1) DK1492789T3 (da)
DO (1) DOP2003000624A (da)
EA (1) EA007590B1 (da)
ES (1) ES2263960T3 (da)
GE (1) GEP20074210B (da)
HK (1) HK1076102A1 (da)
HN (1) HN2003000114A (da)
HR (1) HRP20040940A2 (da)
IL (1) IL164261A0 (da)
IS (1) IS2577B (da)
MA (1) MA27190A1 (da)
MX (1) MXPA04009220A (da)
MY (1) MY134223A (da)
NI (1) NI200300053A (da)
NO (1) NO329674B1 (da)
NZ (1) NZ535452A (da)
OA (1) OA12798A (da)
PA (1) PA8570801A1 (da)
PE (1) PE20040082A1 (da)
PL (1) PL372968A1 (da)
PT (1) PT1492789E (da)
RS (1) RS51550B (da)
SI (1) SI1492789T1 (da)
TN (1) TNSN04194A1 (da)
TW (1) TWI280130B (da)
UY (1) UY27752A1 (da)
WO (1) WO2003084954A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309118A (pt) * 2002-04-08 2005-02-01 Pfizer Derivados de tropano úteis em terapêutica
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
SI1682545T1 (sl) * 2003-10-03 2008-04-30 Pfizer Derivati tropana, substituirani z imidazopiridinom, z antagonisticno aktivnostjo receptorja CCR5 zazdravljenje HIV in vnetja
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8131026B2 (en) 2004-04-16 2012-03-06 Validity Sensors, Inc. Method and apparatus for fingerprint image reconstruction
WO2006041780A1 (en) 2004-10-04 2006-04-20 Validity Sensors, Inc. Fingerprint sensing assemblies comprising a substrate
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
PL2134712T3 (pl) 2007-04-13 2014-01-31 Dong Wha Pharm Co Ltd Asparaginian kwasu 1-cyklopropylo-6-fluoro-7-(8-metoksyimino-2,6-diaza-spiro[3.4]okt-6-ylo)-4-okso-1,4-dihydro-[1,8]naftyrydyno-3-karboksylowego, sposób jego wytwarzania i zawierająca go przeciwdrobnoustrojowa kompozycja farmaceutyczna
WO2009029257A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Disubstituted alkyl-8-azabicyclo [3.2.1.] octane compounds as mu opioid receptor antagonists
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EA201200855A1 (ru) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. Модуляторы crth2
PE20130529A1 (es) 2010-04-02 2013-05-14 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2016243171B2 (en) 2015-03-31 2020-10-08 Concert Pharmaceuticals, Inc. Deuterated VX-661
US10759721B2 (en) 2015-09-25 2020-09-01 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR potentiators
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN117924170A (zh) 2017-12-01 2024-04-26 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強物質
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2001080106A1 (fr) * 2000-04-19 2001-10-25 Satoshi Yamazaki Procede de diffusion d'outil publicitaire et support magnetique pour le logiciel
PT1526134E (pt) * 2000-05-26 2008-10-28 Pfizer Derivados de triazoliltropano como moduladores de ccr5
BR0309118A (pt) * 2002-04-08 2005-02-01 Pfizer Derivados de tropano úteis em terapêutica

Also Published As

Publication number Publication date
CN1646526A (zh) 2005-07-27
EA007590B1 (ru) 2006-12-29
SI1492789T1 (sl) 2006-10-31
IS7453A (is) 2004-09-16
IL164261A0 (en) 2005-12-18
CA2481482A1 (en) 2003-10-16
NZ535452A (en) 2006-11-30
OA12798A (en) 2006-07-10
PA8570801A1 (es) 2004-11-26
JP3793200B2 (ja) 2006-07-05
PE20040082A1 (es) 2004-03-20
AU2003214503A1 (en) 2003-10-20
MY134223A (en) 2007-11-30
EP1492789A1 (en) 2005-01-05
EA200401167A1 (ru) 2005-04-28
GEP20074210B (en) 2007-10-10
RS88804A (en) 2006-12-15
AU2003214503B2 (en) 2008-08-07
DE60305903T2 (de) 2007-03-08
KR100734685B1 (ko) 2007-07-02
HK1076102A1 (en) 2006-01-06
ATE328882T1 (de) 2006-06-15
DE60305903D1 (de) 2006-07-20
DOP2003000624A (es) 2003-10-15
JP2006182784A (ja) 2006-07-13
BR0309118A (pt) 2005-02-01
CU23282A3 (es) 2008-06-30
NO20044615L (no) 2004-10-26
MXPA04009220A (es) 2005-09-30
AP2004003147A0 (en) 2004-09-30
KR20040099420A (ko) 2004-11-26
EP1492789B1 (en) 2006-06-07
TW200403242A (en) 2004-03-01
PL372968A1 (en) 2005-08-08
MA27190A1 (fr) 2005-01-03
UY27752A1 (es) 2003-11-28
TNSN04194A1 (fr) 2007-03-12
ES2263960T3 (es) 2006-12-16
IS2577B (is) 2010-02-15
AP1789A (en) 2007-10-05
HN2003000114A (es) 2004-05-05
WO2003084954A1 (en) 2003-10-16
HRP20040940A2 (en) 2005-04-30
CR7514A (es) 2004-11-08
JP2005532285A (ja) 2005-10-27
NO329674B1 (no) 2010-11-29
JP4571078B2 (ja) 2010-10-27
AR039383A1 (es) 2005-02-16
PT1492789E (pt) 2006-09-29
TWI280130B (en) 2007-05-01
CA2481482C (en) 2009-11-10
CN1324025C (zh) 2007-07-04
NI200300053A (es) 2005-11-01
CY1106114T1 (el) 2011-06-08
RS51550B (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DK1492789T3 (da) Tropanderivater som CCR5-modulatorer
DK1284974T3 (da) Triazolyltropanderivater som CCR5-modulatorer
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20050426L (no) Arylkarbonylderivater som terapeutiske midler
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK1735286T3 (da) Tetrahydroindazoler som cannabinoidmodulatorer
NO20055135D0 (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NO20023283D0 (no) Flammestopper
DK1611131T3 (da) Pyrazolopyridin-derivater
NO20013149L (no) Piperidiner som CCR5-modulatorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
ATE456558T1 (de) Gabanerge modulatoren
IL177729A0 (en) N-piperidine derivatives as ccr3 modulators
NO20043794L (no) Benzensulfonamidderivater som antipsykotiske midler
NO20035183D0 (no) 5-substituerte-2-arylpyridiner som CRF1 modulatorer
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
DK1853609T3 (da) Thienopyridinderivater og anvendelse deraf som hsp90-modulatorer
ATE361911T1 (de) Piperidinderivate als ccr5-rezeptormodulatoren